Pathophysiological impacts of tafamidis on cardiac transthyretin amyloidosis

Phase 4

Recruiting

• Conditions: Transthyretin amyloidosis; ATTR-CM

• Registration Number: JPRN-jRCT1041200007
• Lead Sponsor: Fujimoto Naoki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

(1)heart failue patients with transthyretin amyloidosis
(2)patients with transthyretin amyloidosis confirmed by myocardial biopsy
(3)patients with LV thickness equal and/or greater than 12 mm
(4)patients wth age equal and/or greater than 20
(5)men and women
(6)patients with NYHA 1 to 3
(7) patients with LV hypertrophy (and diastolic dysfunction) caused by amyloid deposition

Exclusion Criteria

(1) patients with severe valcular disease
(2) patients with NYHA4 heart failure
(3) patients with acute coronary syndrome
(4) patients with cardiogenic shock
(5) patients with severe liver failure
(6) patients with stage 5 kidney disease
(7) patients with infectious disease
(8) patients with a a life expectancy of less than 1 year
(9) pregnant patients
(10) patients who are unable to walk

Study & Design

• Study Type: Interventional
• Study Design: Not specified